Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)
Launched by STANFORD UNIVERSITY · May 5, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a randomized quality improvement (QI) project evaluating the impact of notifying patients and their clinicians (primary care, cardiologists, neurologists, or vascular surgeon) of incidental CAC detected on a prior chest CT scan. Patients will be identified by screening previous non-gated chest CT scans and electronic health records. The presence of CAC will be confirmed by a radiologist. Eligible patients will be randomized to: 1) notification of presence of CAC with a CT scan image; 2) notification of presence of CAC without a CT scan image; 3) or usual care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Presence of CAC on non-gated chest CT scans performed from 2021 to 2023
- • 2. Age \<85 years
- • 3. Diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease
- 4. Visit to Stanford affiliated clinician since 2021 at one of the following Stanford clinics including University affiliated clinics:
- • 1. Internal Medicine
- • 2. Family Medicine
- • 3. Cardiology
- • 4. Neurology
- • 5. Vascular surgery
- Exclusion Criteria:
- • 1. No diagnosis of ASCVD
- • 2. Patients receiving lipid-lowering therapy
- • 3. Dementia
- • 4. Metastatic cancer or active cancer undergoing chemotherapy
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported